Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Grunda, Jessica M ^a   Steg, Adam D ^b   He, Qinghua ^c   Steciuk, Mark R ^d   Byan Parker, Suzanne ^d   Johnson, Martin R ^e   Grizzle, William E ^d  

^a and Clinical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TUSKEGEE UNIVERSITY   (United States)

^d University of Alabama at Birmingham   (United States)

^e The Purdue Univ Univ of Alabama at Birmingham Botanical Center for Age Related Disease   (United States)

Author keywords

Breast cancer; Cell cycle; Cell migration; Estrogen signaling; Gene expression; Race

Indexed keywords

TUMOR MARKER;

AFRICAN AMERICAN; AGE; ARTICLE; BIOPSY; BREAST TUMOR; CANCER STAGING; CAUCASIAN; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; ETHNOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

AFRICAN AMERICANS; AGE FACTORS; BIOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861205946     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-248     Document Type: Article

References (106)

1. Society AC, Breast cancer facts and figures: 2009-2010 American Cancer Society, Inc., Atlanta 2009
2. Society AC, Cancer Fact and Figures for African Americans 2011-2012 American Cancer Society, Atlanta 2011
3. Breast cancer in African-American women. Newman LA, Oncologist 2005 10 1 1 14 10.1634/theoncologist.10-1-1 16368866
4. Histological characteristics of breast carcinoma in blacks and whites. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, Muss H, Hunter CP, Redmond C, Sobhan M, et al. Canc Epidemiol Biomarkers Prev 1994 3 2 127 135 (Pubitemid 24170054)
5. Race and ethnicity are associated with delays in breast cancer treatment (2003-2006). Fedewa SA, Edge SB, Stewart AK, Halpern MT, Marlow NM, Ward EM, J Health Care Poor Underserved 2011 22 1 128 141 21317511
6. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. Fedewa SA, Ward EM, Stewart AK, Edge SB, J Clin Oncol 2010 28 27 4135 4141 10.1200/JCO.2009.27.2427 20697082
7. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL, Cancer 2011 117 1 180 189 10.1002/cncr.25542 20939011
8. The influence of spirituality and religiosity on breast cancer screening delay in African American women: application of the Theory of Reasoned Action and Planned Behavior (TRA/TPB). Gullate M, ABNF J 2006 17 2 89 94 18402350
9. Dietary fat, cooking fat, and breast cancer risk in a multiethnic population. Wang J, John EM, Horn-Ross PL, Ingles SA, Nutr Cancer 2008 60 4 492 504 10.1080/01635580801956485 18584483 (Pubitemid 351918541)
10. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA, J Clin Oncol 2006 24 9 1342 1349 10.1200/JCO.2005.03.3472 16549828 (Pubitemid 46621996)
11. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Newman LA, Mason J, Cote D, Vin Y, Carolin K, Bouwman D, Colditz GA, Cancer 2002 94 11 2844 2854 10.1002/cncr.10575 12115371 (Pubitemid 34547682)
12. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U.S. Department of Defense Healthcare system. Jatoi I, Becher H, Leake CR, Cancer 2003 98 5 894 899 10.1002/cncr.11604 12942554 (Pubitemid 37022087)
13. Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Wojcik BE, Spinks MK, Optenberg SA, Cancer 1998 82 7 1310 1318 10.1002/(SICI)1097-0142(19980401)82:7<1310::AID- CNCR14>3.0.CO;2-9 9529023 (Pubitemid 28155393)
14. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. Albain KS, Unger JM, Crowley JJ, Coltman CA, Hershman DL, J Natl Cancer Inst 2009 101 14 984 992 10.1093/jnci/djp175 19584328
15. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. JAMA 2006 295 21 2492 2502 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
16. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Clin Cancer Res 2004 10 16 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 (Pubitemid 39100473)
17. Breast cancer in African-American women: differences in tumor biology from European-American women. Amend K, Hicks D, Ambrosone CB, Cancer Res 2006 66 17 8327 8330 10.1158/0008-5472.CAN-06-1927 16951137 (Pubitemid 44449138)
18. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA, Ann Surg Oncol 2007 14 10 2994 3003 10.1245/s10434-007-9477-6 17647064 (Pubitemid 47460642)
19. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM, Cancer 1991 68 2 331 334 10.1002/1097-0142(19910715)68:2<331::AID-CNCR2820680221>3.0.CO;2-X 1676930
20. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW, Cancer 2004 100 12 2533 2542 10.1002/cncr.20279 15197793 (Pubitemid 38715756)
21. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO, Histopathology 2005 46 6 685 693 10.1111/j.1365-2559.2005.02156.x 15910600 (Pubitemid 40834828)
22. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, ORegan RM, Gabram SG, Eley JW, Breast Cancer Res Treat 2009 113 2 357 370 10.1007/s10549-008-9926-3 18324472
23. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW, Cancer 2009 115 10 2222 2233 10.1002/cncr.24200 19241424
24. Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer, Ellsworth RE 2011
25. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. Arch Pathol Lab Med 2010 134 6 907 922 20524868
26. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME, Arch Pathol Lab Med 2009 133 4 611 612 19391661
27. Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies. Steg A, Vickers SM, Eloubeidi M, Wang W, Eltoum IA, Grizzle WE, Saif MW, Lobuglio AF, Frost AR, Johnson MR, Diagn Mol Pathol 2007 16 4 229 237 10.1097/PDM. 0b013e31811edc7e 18043287 (Pubitemid 350196981)
28. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Blanquicett C, Johnson MR, Heslin M, Diasio RB, Anal Biochem 2002 303 2 209 214 10.1006/abio.2001.5570 11950223 (Pubitemid 34407587)
29. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, et al. J Mol Diagn 2006 8 1 76 83 10.2353/jmoldx.2006.040402 16436637 (Pubitemid 43257437)
30. Fisher RA, Statistical Methods for Research Workers Oliver and Boyd, 1954
31. Nonparametric Statistical Methods. Hallander M, Wolfe D, 1999 (2nd)
32. Semi-supervised methods to predict patient survival from gene expression data. Bair E, Tibshirani R, PLoS Biol 2004 2 4 108 10.1371/journal.pbio.0020108 15094809 (Pubitemid 39234509)
33. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, et al. N Engl J Med 2009 360 5 470 480 10.1056/NEJMoa0808253 19129520
34. The Kolmogorov-Smirnov test for goodness of fit. Massey F, J Am Stat Assoc 1951 46 253 68 78 10.1080/01621459.1951.10500769
35. Johnson R, Wichern D, Applied Multivariate Statistical Analysis Prentice-Hall, Inc, 1982
36. RNA expression analysis from formalin fixed paraffin embedded tissues. Farragher SM, Tanney A, Kennedy RD, Paul Harkin D, Histochem Cell Biol 2008 130 3 435 445 10.1007/s00418-008-0479-7 18679706
37. Excavation of a buried treasure-DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Klopfleisch R, Weiss AT, Gruber AD, Histol Histopathol 2011 26 6 797 810 21472693
38. Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, et al. J Neurooncol 2006 80 3 261 274 10.1007/s11060-006-9191-4 16773218 (Pubitemid 44782903)
39. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM, Nat Med 1997 3 2 222 225 10.1038/nm0297-222 9018243 (Pubitemid 27064709)
40. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, et al. Nat Med 1997 3 2 227 230 10.1038/nm0297-227 9018244 (Pubitemid 27064710)
41. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C, Mol Med 1998 4 12 807 822 9990866 (Pubitemid 29180127)
42. P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Han S, Ahn SH, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY, Breast Cancer Res Treat 2001 70 3 205 212 10.1023/A:1013047413895 11804184 (Pubitemid 34015516)
43. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T, Breast Cancer Res Treat 2001 67 1 61 70 10.1023/A:1010623308275 11518467 (Pubitemid 32703389)
44. Cyclins and breast cancer. Steeg PS, Zhou Q, Breast Cancer Res Treat 1998 52 1-3 17 28 10066069 (Pubitemid 29056082)
45. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Satyanarayana A, Kaldis P, Oncogene 2009 28 33 2925 2939 10.1038/onc.2009.170 19561645
46. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J, Br J Cancer 1996 73 6 728 734 10.1038/bjc.1996.128 8611372 (Pubitemid 26105298)
47. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Christov K, Ikui A, Shilkaitis A, Green A, Yao R, You M, Grubbs C, Steele V, Lubet R, Weinstein IB, Breast Cancer Res Treat 2003 77 3 253 264 10.1023/A:1021804121171 12602925 (Pubitemid 36197640)
48. G1-S transition defects occur in most breast cancers and predict outcome. Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G, Breast Cancer Res Treat 1999 56 2 105 112 10573103 (Pubitemid 29494828)
49. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM, Int J Cancer 1998 79 1 71 75 10.1002/(SICI)1097- 0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K 9495362 (Pubitemid 28157730)
50. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, et al. J Natl Cancer Inst 2005 97 6 439 448 10.1093/jnci/dji064 15770008 (Pubitemid 40528607)
51. Hormone receptors in breast cancer: racial differences in distribution and survival. Joslyn SA, Breast Cancer Res Treat 2002 73 1 45 59 10.1023/A:1015220420400 12083631 (Pubitemid 34548165)
52. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. Elledge RM, Clark GM, Chamness GC, Osborne CK, J Natl Cancer Inst 1994 86 9 705 712 10.1093/jnci/86.9.705 7908990 (Pubitemid 24138977)
53. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW, Cancer 2001 92 1 37 45 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F 11443607 (Pubitemid 32623038)
54. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Callahan R, Hurvitz S, Curr Opin Obstet Gynecol 2011 23 1 37 43 10.1097/GCO.0b013e3283414e87 21500375
55. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, Mottolese M, De Placido S, Querzoli P, Jirillo A, et al. Breast Cancer Res Treat 2011 128 1 147 154 10.1007/s10549-011-1484-4 21479926
56. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Burris HA, Expert Opin Biol Ther 2011 11 6 807 819 10.1517/14712598.2011.580273 21506905
57. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I, Endocr Relat Cancer 2006 13 4 1109 1120 10.1677/erc.1.01120 17158757 (Pubitemid 46212566)
58. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Wilson BJ, Giguere V, Mol Cancer 2008 7 49 10.1186/1476-4598-7-49 18533032 (Pubitemid 351891429)
59. Bcl-2 expression and triple negative profile in breast carcinoma. Kallel-Bayoudh I, Hassen HB, Khabir A, Boujelbene N, Daoud J, Frikha M, Sallemi-Boudawara T, Aifa S, Rebai A, Med Oncol 2010 28 Suppl 1 55 S61 20890735
60. CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer. Spyratos F, Andrieu C, Vidaud D, Briffod M, Vidaud M, Lidereau R, Bieche I, Int J Biol Markers 2000 15 3 210 214 11012095
61. Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop. Marconett CN, Sundar SN, Poindexter KM, Stueve TR, Bjeldanes LF, Firestone GL, Mol Biol Cell 2010 21 7 1166 1177 10.1091/mbc.E09-08-0689 20130088
62. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG, Canc Res 2005 65 24 11259 11264 10.1158/0008-5472.CAN-05-2495 (Pubitemid 41821679)
63. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO, Mod Pathol 2005 18 10 1295 1304 10.1038/modpathol.3800445 15976813 (Pubitemid 41348648)
64. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Wei X, Xu H, Kufe D, Mol Cell 2006 21 2 295 305 10.1016/j.molcel.2005.11.030 16427018 (Pubitemid 43099944)
65. Emerging biomarkers in breast cancer care. Napieralski R, Brunner N, Mengele K, Schmitt M, Biomark Med 2010 4 4 505 522 10.2217/bmm.10.73 20701440
66. Markers of the uPA system and common prognostic factors in breast cancer. Minisini AM, Fabbro D, Di Loreto C, Pestrin M, Russo S, Cardellino GG, Andreetta C, Damante G, Puglisi F, Am J Clin Pathol 2007 128 1 112 117 10.1309/M0GXVXA89BVLJ5C9 17580278 (Pubitemid 47121723)
67. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Smith LH, Coats SR, Qin H, Petrie MS, Covington JW, Su M, Eren M, Vaughan DE, Circ Res 2004 95 3 269 275 10.1161/01.RES.0000136521.70093.f1 15217907 (Pubitemid 39056287)
68. Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Cimino D, Fuso L, Sfiligoi C, Biglia N, Ponzone R, Maggiorotto F, Russo G, Cicatiello L, Weisz A, Taverna D, et al. Int J Canc J Int du cancer 2008 123 6 1327 1338
69. mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Yamamura J, Miyoshi Y, Tamaki Y, Taguchi T, Iwao K, Monden M, Kato K, Noguchi S, Cancer Sci 2004 95 11 887 892 10.1111/j.1349-7006. 2004.tb02198.x 15546506 (Pubitemid 40045523)
70. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ, Canc Res 2002 62 5 1289 1295 (Pubitemid 34407780)
71. Up-regulation of pituitary [125I]insulin-like growth factor-I (IGF-I) binding and IGF binding protein-2 and IGF-I gene expression by estrogen. Michels KM, Lee WH, Seltzer A, Saavedra JM, Bondy CA, Endocrinology 1993 132 1 23 29 10.1210/en.132.1.23 7678216 (Pubitemid 23019477)
72. IGF-I, IGF-II, free IGF-I and IGF-binding proteins-2 to 6 during high-dose oestrogen treatment in constitutionally tall girls. Rooman RP, De Beeck LO, Martin M, Van Doorn J, Mohan S, Du Caju MV, Eur J Endocrinol 2002 146 6 823 829 10.1530/eje.0.1460823 12039703 (Pubitemid 34705075)
73. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB, Endocrine-related cancer 2006 13 2 617 628 10.1677/erc.1.01165 16728587 (Pubitemid 43886681)
74. Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. Graham JD, Roman SD, McGowan E, Sutherland RL, Clarke CL, J Biol Chem 1995 270 51 30693 30700 10.1074/jbc.270.51.30693 8530508 (Pubitemid 26005135)
75. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P, Embo J 1990 9 5 1603 1614 2328727
76. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women. Saucedo R, Basurto L, Zarate A, Martinez C, Hernandez M, Galvan R, Gynecol Obstet Invest 2007 64 2 61 64 10.1159/000099148 17264514 (Pubitemid 47294458)
77. Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies. Adams DJ, Hajj H, Edwards DP, Bjercke RJ, McGuire WL, Can Res 1983 43 9 4297 4301 (Pubitemid 13044055)
78. Immunocytochemical determination of the estrogen-regulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy. Andersen J, Skovbon H, Poulsen HS, Eur J Cancer Clin Oncol 1989 25 4 641 643 10.1016/0277-5379(89)90198-3 2714341 (Pubitemid 19096431)
79. Estrogen-induced 24 K protein in MCF-7 breast cancer cells is localized in granules. Ciocca DR, Adams DJ, Edwards DP, Bjercke RJ, McGuire WL, Breast Canc Res Treat 1984 4 4 261 268 10.1007/BF01806037 (Pubitemid 15189794)
80. Estrogen-dependent release of serum proteins from MCF-7 breast carcinoma cells in vitro. Kroll J, Briand P, Anticancer Res 1988 8 1 89 91 3258740
81. Estradiol increases the production of alpha 1-antichymotrypsin in MCF7 and T47D human breast cancer cell lines. Massot O, Baskevitch PP, Capony F, Garcia M, Rochefort H, Mol Cell Endocrinol 1985 42 3 207 214 10.1016/0303-7207(85)90050-4 3899774 (Pubitemid 15012053)
82. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, et al. Brit J Canc 2010 103 5 668 675 10.1038/sj.bjc.6605736
83. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y, Breast Canc Res 2008 10 2 35 10.1186/bcr1998
84. Cyclin D1 and prognosis in human breast cancer. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D, Int J Cancer 1996 69 2 92 99 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q 8608989 (Pubitemid 26167163)
85. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM, J Clin Oncol: Official Journal of the American Society of Clinical Oncology 2006 24 11 1656 1664 10.1200/JCO.2005.03.2755 (Pubitemid 46622136)
86. Higher levels of GATA3 predict better survival in women with breast cancer. Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, Mah V, Bose S, Chia D, Chang HR, et al. Hum Pathol 2010 41 12 1794 1801 10.1016/j.humpath.2010.06.010 21078439
87. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A, Cancer 2000 88 9 2061 2071 10.1002/(SICI)1097-0142(20000501)88:9<2061::AID-CNCR12>3.0.CO;2-O 10813718 (Pubitemid 30233208)
88. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkila R, Kvaloy JT, Gilje B, Smaaland R, Nordgard O, Clin Breast Cancer 2010 10 5 378 384 10.3816/CBC.2010.n.050 20920982
89. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J, Histopathology 2007 51 3 322 335 10.1111/j.1365-2559.2007.02757.x 17645748 (Pubitemid 47301607)
90. Progesterone receptors and human breast cancer. Clark GM, McGuire WL, Breast Canc Res Treat 1983 3 2 157 163 10.1007/BF01803558 (Pubitemid 13040294)
91. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM, Clin Canc Res: an official Journal of the American Association for Cancer Research 2007 13 11 3164 3173 10.1158/1078-0432.CCR-07-0224 (Pubitemid 46944898)
92. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F, Virchows Arch 2006 449 1 24 30 10.1007/s00428-006-0213-6 16628414 (Pubitemid 43988362)
93. Physiology and function of the tight junction. Anderson JM, Van Itallie CM, Cold Spring Harb Perspect Biol 2009 1 2 002584 10.1101/cshperspect.a002584 20066090
94. Claudins: unlocking the code to tight junction function during embryogenesis and in disease. Gupta IR, Ryan AK, Clin Genet 2010 77 4 314 325 10.1111/j.1399-0004.2010.01397.x 20447145
95. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Morin PJ, Cancer Res 2005 65 21 9603 9606 10.1158/0008-5472.CAN-05- 2782 16266975 (Pubitemid 41541431)
96. Claudin 7 expression and localization in the normal murine mammary gland and murine mammary tumors. Blackman B, Russell T, Nordeen SK, Medina D, Neville MC, Breast Cancer Res 2005 7 2 248 R255 10.1186/bcr988 15743505
97. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S, Oncogene 2003 22 13 2021 2033 10.1038/sj.onc.1206199 12673207 (Pubitemid 36523639)
98. Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Sauer T, Pedersen MK, Ebeltoft K, Naess O, Cytopathology 2005 16 4 193 198 10.1111/j.1365-2303.2005. 00257.x 16048505 (Pubitemid 41112978)
99. DLC1: a significant GAP in the cancer genome. Lahoz A, Hall A, Genes Dev 2008 22 13 1724 1730 10.1101/gad.1691408 18593873 (Pubitemid 351915495)
100. Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. Sekimata M, Kabuyama Y, Emori Y, Homma Y, J Biol Chem 1999 274 25 17757 17762 10.1074/jbc.274.25.17757 10364218 (Pubitemid 29283295)
101. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Zhou X, Thorgeirsson SS, Popescu NC, Oncogene 2004 23 6 1308 1313 10.1038/sj.onc.1207246 14647417 (Pubitemid 38297186)
102. Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7). Durkin ME, Yuan BZ, Thorgeirsson SS, Popescu NC, Gene 2002 288 1-2 119 127 12034501 (Pubitemid 34595369)
103. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS, Popescu NC, Oncogene 2003 22 3 445 450 10.1038/sj.onc.1206064 12545165 (Pubitemid 36194340)
104. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC, Cancer Res 1998 58 10 2196 2199 9605766 (Pubitemid 28232908)
105. Analysis of DLC-1 expression in human breast cancer. Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S, J Cancer Res Clin Oncol 2003 129 6 349 354 10.1007/s00432-003-0440-z 12759748 (Pubitemid 36963197)
106. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Holeiter G, Heering J, Erlmann P, Schmid S, Jahne R, Olayioye MA, Cancer Res 2008 68 21 8743 8751 10.1158/0008-5472.CAN-08- 0984 18974116